Zhejiang Huahai Pharmaceutical (600521.SH) obtains registration certificate for orally disintegrating tablets of enalapril maleate and alprazolam oral solution.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company and its subsidiary, Changxing Pharmaceutical Co., Ltd. (referred to as "Changxing Pharmaceutical", securities code: 835269), recently received the Drug Registration Certificate issued by the National Medical Products Administration for the production of Enalapril Maleate Tablets and Aripiprazole Oral Solution. Enalapril Maleate Tablets are mainly used for the treatment of primary hypertension at various stages, renal vascular hypertension, various stages of heart failure, prevention of symptomatic heart failure, and prevention of coronary artery ischemic events in patients with left ventricular dysfunction. Aripiprazole Oral Solution is mainly used to treat schizophrenia in adolescents aged 13-17 and adults. The company's Enalapril Maleate Tablets and Changxing Pharmaceutical's Aripiprazole Oral Solution have obtained the Drug Registration Certificate from the National Medical Products Administration, further enriching the company's product line and enhancing its market competitiveness. According to relevant national policies, the registration approval of these products is equivalent to passing a consistency assessment, and medical institutions will prioritize their procurement and use in clinical settings, which will have a positive impact on the company's business performance.